Herpes Infection Treatment Market Size, Share & Trends Analysis Report By Product (Therapeutics, Vaccine), By Type (HSV), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 To 2030

The growth of the herpes infection treatment market is attributed to an increasing prevalence of herpes infection globally and growing awareness about the disease. For instance, according to WHO, in 2020, nearly 50 million of the population were suffering from genital herpes caused by type 1 or type 2 of the herpes simplex virus HSV, and several billion people have oral infections. The asymptomatic nature of the condition, escalates its transmission rate, thereby creating a market opportunity for treatments.

The therapeutics segment includes drugs of which valacyclovir drug dominated the market as it is cost-effective, readily available, and effective in blocking the virus from reproducing in the body, thereby aiding to control the symptoms of an outbreak. Moreover, valacyclovir is most widely used for cold sores attributable to its higher absorption rate. There are efforts and investments that have been done to provide vaccination for the disease condition which is expected to boost the growth of the vaccine segment. Key players operating in the herpes infection marketplace are focusing on developing vaccines, for instance, in July 2021, GlaxoSmithKline plc announced the U.S. FDA approval of Shingrix for the prevention of shingles caused by herpes zoster.

North America dominated the overall market in 2021 which can be attributed to escalating healthcare expenditure, higher consumption of branded herpes infection treatment drugs, increasing launch of generics, and favorable reimbursement policies. Increasing disease prevalence, and growing geriatric and immunocompromised population in the region are increasing awareness among the population which further propels the growth of the market. For instance, in 2021, according to CDC, HSV was one of the most prevalent sexually transmitted infections in the United States. Furthermore, to meet the high demand for effective treatment options, major key players are focusing on expanding their product portfolios. For instance, in 2022, Moderna, Inc. expanded its mRNA pipeline with three new development programs to reduce the rates of shingles. 

Herpes Infection Treatment Market Segmentation

Major companies operating in the market include Teva Pharmaceutical Industries Ltd.; Abbott; GlaxoSmithKline plc; Cipla Inc.; Eli Lilly and Company; Merck & Co., Inc.; Novartis AG; F. Hoffmann-La Roche Ltd. These players are focusing on mergers and acquisition to maintain its presence over the market. For instance, in January 2022, Pfizer and BioNTech signed a collaboration agreement to develop first mRNA-based shingles infection vaccine. This agreement aims to accelerate the development of an improved vaccine for shingles infection.